Dr. Bray Links

Monday, November 17, 2014

Study Finds Alternative to Anti-Cholesterol Drug - NYTimes.com

 
Zetia is now an validated option for folks needing to reduce cholesterol levels. Keep in mind that fiber - like the kind found in whole organic apples - is also very effective at lowering cholesterol through a similar mechanism.
 
-CB
 
---
 
Both groups ended up with very low LDL levels — those taking the statin, simvastatin, had an average LDL of 69, and those taking simvastatin and the other drug, ezetimibe, or Zetia, in a combination pill sold as Vytorin, had an average LDL of 54. No clinical trial had ever asked what happened when LDL levels get below 70 because, said Dr. Robert Califf, a Duke cardiologist and the study chairman, "many people were nervous about going this low and imagined a lot of possible toxicities."
 
 
---
 
"Apples would give a similar boost to cardiovascular health as medicines, such as statins, yet carry none of the side-effects, the University of Oxford researchers say in the BMJ."
 
http://www.bmj.com/content/347/bmj.f7267

---

"There is increased risk of diabetes mellitus, cataract formation, and erectile dysfunction in young statin users, all of which are alarming. Furthermore there is a significant increase in the risk of cancer and neurodegenerative disorders in the elderly plus an enhanced risk of a myriad of infectious diseases.

All side effects are dose dependent and persist during treatment.

Primary prevention clinical results provoke the possibility of not only the lack of primary cardiovascular protection by statin therapy but highlight the very real possibility of augmented cardiovascular risk in women, patients with Diabetes Mellitus and the young . Statins are associated with triple the risk of coronary artery and aortic calcification. These finding on statin major adverse effects had been under-reported and the way in which they withheld from the public, and even concealed, is a scientific farce."

http://www.scirp.org/journal/PaperDownload.aspx?paperID=34065

No comments:

Post a Comment